Diproqualone
From Wikipedia, the free encyclopedia
Diproqualone
|
|
Systematic (IUPAC) name | |
3-(2,3-dihydroxypropyl)-2-methyl-quinazolin-4-one | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C12H14N2O3 |
Mol. mass | 234.251 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Diproqualone is an analogue of methaqualone developed in the 1980s and marketed mainly in France and some other european countries. It has sedative, anxiolytic, antihistamine and analgesic properties, and is used primarily for the treatment of inflammatory pain associated with osteoarthritis and rheumatoid arthritis[1], and more rarely for treating insomnia, anxiety and neuralgia. [2]
Diproqualone is the only analogue of methaqualone that is still in widespread clinical use, due to its useful anti-inflammatory and analgesic effects in addition to the sedative and anxiolytic actions common to other drugs of this class. There are still some concerns about the potential of diproqualone for abuse and overdose, and so it is not sold as a pure drug but only as the camphosulfonate salt in combination mixtures with other medicines such as Ethenzamide.
[edit] See also
[edit] References
- ^ Audeval B, Bouchacourt P, Rondier J. Comparative study of diproqualone-ethenzamide versus glafenine for the treatment of rheumatic pain of gonarthrosis and coxarthrosis. (French) Gazette médicale de France 1988; 95(25):70-72
- ^ Substances Actives : CAMSILATE DE DIPROQUALONE